無料セミナー : 2020年3月4日『Future of Immuno-Oncology 免疫腫瘍学の未来』 DelveInsight Business Research共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

全身型重症筋無力症(gMG):2028年までの疫学予測

Generalized Myasthenia Gravis (gMG) - Epidemiology Forecast to 2028

発行 DelveInsight Business Research LLP 商品コード 905937
出版日 ページ情報 英文 87 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
全身型重症筋無力症(gMG):2028年までの疫学予測 Generalized Myasthenia Gravis (gMG) - Epidemiology Forecast to 2028
出版日: 2019年08月01日 ページ情報: 英文 87 Pages
概要

当レポートは世界の全身型重症筋無力症(gMG)について調査しており、疾患の概要、MGFA分類、患者人口、米国・ドイツ・フランス・イタリア・スペイン・英国・日本の主要7か国の疫学などの情報を提供しています。

目次

第1章 重要な洞察

第2章 全身型重症筋無力症:疫学の概要

  • 患者シェア(%)2017年の分布
  • 患者シェア(%)2028年の分布

第3章 疾患の概要:全身型重症筋無力症

  • イントロダクション
  • 重症筋無力症の種類
    • 目の重症筋無力症
    • 全身型重症筋無力症
  • 重症筋無力症のMGFA分類
  • 病因
  • 危険因子
  • 兆候および症状
  • MGの併存疾患
  • 遺伝的根拠
  • 病態生理
    • 自己抗体
    • 補数カスケード
  • バイオマーカー
  • 診断
    • 鑑別診断
    • 日本の診断基準

第4章 疫学および患者人口

  • 主な調査結果
  • 人口および予測パラメータ
  • 主要7ヶ国の総患者数
  • 国別の疫学
  • 米国
    • 仮定および根拠
    • 米国における総診断例
    • 自己抗体-米国における全身性重症筋無力症の具体例
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

第5章 市場成長要因

第6章 市場の障壁

第7章 付録

第8章 レポート方法

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 免責事項

図表

List of Tables

  • Table 1: Osserman and Genkins Classification of Myasthenia Gravis, modified by the MGFA/Task Force
  • Table 2: Summary of the tests used in the diagnosis of myasthenia gravis
  • Table 3: Proposed diagnostic criteria for myasthenia gravis - Japanese Treatment guidelines
  • Table 4: Diagnosed Prevalent Patient Population of Generalized Myasthenia Gravis in 7MM (2017-2028)
  • Table 5: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the United States (2017-2028)
  • Table 6: Autoantibodies specific cases of Myasthenia Gravis in the United States (2017-2028)
  • Table 7: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Germany (2017-2028)
  • Table 8: Autoantibodies specific cases of Generalized Myasthenia Gravis in Germany (2017-2028)
  • Table 9: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in France (2017-2028)
  • Table 10: Autoantibodies specific cases of Generalized Myasthenia Gravis in France (2017-2028)
  • Table 11: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Italy (2017-2028)
  • Table 12: Autoantibodies specific cases of Generalized Myasthenia Gravis in Italy (2017-2028)
  • Table 13: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Spain (2017-2028)
  • Table 14: Autoantibodies specific cases of Generalized Myasthenia Gravis in Spain (2017-2028)
  • Table 15: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the UK (2017-2028)
  • Table 16: Autoantibodies specific cases of Generalized Myasthenia Gravis in the UK (2017-2028)
  • Table 17: Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Japan (2017-2028)
  • Table 18: Autoantibodies specific cases of Generalized Myasthenia Gravis in Japan (2017-2028)

List of Figures

  • Figure 1: Transmission of Nerve Impulses to Muscles
  • Figure 2: Signs and Symptoms of Generalized Myasthenia Gravis
  • Figure 3: Various Components of the Neuromuscular Junction involved in MG
  • Figure 4: Various Components of the Neuromuscular Junction involved in MG
  • Figure 5: Pathophysiology of MG at the neuromuscular junction
  • Figure 6: Complement cascade
  • Figure 7: Diagnostic testing in myasthenia gravis
  • Figure 8: Diagnosis flowchart for MG
  • Figure 9: Diagnosed Prevalent Patient Population of Generalized Myasthenia Gravis in 7MM (2017-2028)
  • Figure 10: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the United States (2017-2028)
  • Figure 11: Autoantibodies-specific cases of Myasthenia Gravis in the US (2017-2028)
  • Figure 12: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Germany (2017-2028)
  • Figure 13: Autoantibodies specific cases of Generalized Myasthenia Gravis in Germany (2017-2028)
  • Figure 14: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in France (2017-2028)
  • Figure 15: Autoantibodies specific cases of Generalized Myasthenia Gravis in France (2017-2028)
  • Figure 16: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Italy (2017-2028)
  • Figure 17: Autoantibodies specific cases of Generalized Myasthenia Gravis in Italy (2017-2028)
  • Figure 18: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Spain (2017-2028)
  • Figure 19: Autoantibodies specific cases of Generalized Myasthenia Gravis in Spain (2017-2028)
  • Figure 20: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the UK (2017-2028)
  • Figure 21: Autoantibodies specific cases of Generalized Myasthenia Gravis in the UK (2017-2028)
  • Figure 22: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Japan (2017-2028)
  • Figure 23: Autoantibodies specific cases of Generalized Myasthenia Gravis in Japan (2017-2028)
  • Figure 24: Unmet needs
  • Figure 25: Market Drivers
  • Figure 23: Market Barriers
目次
Product Code: DIEI0369

DelveInsight's 'Generalized Myasthenia Gravis (gMG)-Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Generalized Myasthenia Gravis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Generalized Myasthenia Gravis Epidemiology

The Generalized Myasthenia Gravis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Generalized Myasthenia Gravis are studied through all possible division to give a better understanding of the disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Generalized Myasthenia Gravis Epidemiology Segmentation

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The epidemiology is segmented by total diagnosed prevalent cases and auto-antibodies specific cases [Anti-AchR Ab (+ve), Anti-MuSK Ab (+ve), Double seronegative] covering the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2028.

According to DelveInsight, total diagnosed prevalent population of Generalized Myasthenia Gravis (gMG) in seven major markets was found to be 58,828 in 2017.

Report Scope

  • The report covers a detailed overview of Generalized Myasthenia Gravis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The report provides insight into the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, and the UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Generalized Myasthenia Gravis.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by auto-antibodies-specific cases of Generalized Myasthenia Gravis in 7MM.

Key strengths

  • 10 Year Forecast of Generalized Myasthenia Gravis epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Generalized Myasthenia Gravis
  • Prevalent Cases according to segmentation: auto-antibodies specific cases

Key assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Generalized Myasthenia Gravis: Epidemiology Overview at a Glance

  • 2.1. Patient Share (%) Distribution of gMG in 2017
  • 2.2. Patient Share (%) Distribution of gMG in 2028

3. Disease Overview: Generalized Myasthenia Gravis

  • 3.1. Introduction
  • 3.2. Types of Myasthenia Gravis
    • 3.2.1. Ocular Myasthenia Gravis
    • 3.2.2. Generalized Myasthenia Gravis
  • 3.3. MGFA Classification of Myasthenia Gravis
  • 3.4. Etiology
  • 3.5. Risk Factors
  • 3.6. Signs and Symptoms
  • 3.7. Comorbid conditions in MG
  • 3.8. Genetic Basis of Generalized Myasthenia Gravis
  • 3.9. Pathophysiology of Generalized Myasthenia Gravis
    • 3.9.1. Autoantibodies
    • 3.9.2. Complement cascade
  • 3.10. Biomarkers in Generalized Myasthenia Gravis
  • 3.11. Diagnosis
    • 3.11.1. Differential Diagnosis
    • 3.11.2. Japanese diagnostic criteria for Myasthenia Gravis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. 7MM Total Diagnosed Prevalent Patient Population of Generalized Myasthenia Gravis
  • 4.4. Country Wise-Epidemiology of Myasthenia Gravis
  • 4.5. United States
    • 4.5.1. Assumptions and Rationale
    • 4.5.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in the US
    • 4.5.3. Autoantibodies- Specific Cases of Generalized Myasthenia Gravis in the US
  • 4.6. Germany
    • 4.6.1. Assumptions and Rationale
    • 4.6.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Germany
    • 4.6.3. Autoantibodies Specific Cases of Generalized Myasthenia Gravis in Germany
  • 4.7. France
    • 4.7.1. Assumptions and Rationale
    • 4.7.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in France
    • 4.7.3. Autoantibodies Specific Cases of Generalized Myasthenia Gravis in France
  • 4.8. Italy
    • 4.8.1. Assumptions and Rationale
    • 4.8.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Italy
    • 4.8.3. Autoantibodies Specific Cases of Generalized Myasthenia Gravis in Italy
  • 4.9. Spain
    • 4.9.1. Assumptions and Rationale
    • 4.9.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Spain
    • 4.9.3. Autoantibodies Specific Cases of Generalized Myasthenia Gravis in Spain
  • 4.10. United Kingdom
    • 4.10.1. Assumptions and Rationale
    • 4.10.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in the United Kingdom
    • 4.10.3. Autoantibodies Specific Cases of Generalized Myasthenia Gravis in the UK
  • 4.11. Japan
    • 4.11.1. Assumptions and Rationale
    • 4.11.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Japan
    • 4.11.3. Autoantibodies Specific Cases of Generalized Myasthenia Gravis in Japan

5. Market Drivers

6. Market Barriers

7. Appendix

8. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Disclaimer

Back to Top